Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety and Efficacy Clear all
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
View directory record Official record
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

NCT02249182
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855
View directory record Official record
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT01623115
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Solbinsiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Prospective, Single Center, Single-Arm Clinical Study of 20 Participants to Reduce the Appearance of the Peri-orbital Wrinkles. Participants Will Receive up to Four Treatments With Tixel Every 4 Weeks. Follow-up Will Occur 1 Month and 3 Months Following Last Treatment.

NCT05282979
View directory record Official record
Conditions
Wrinkle
Interventions
Tixel 2
Device
Lead sponsor
Physicians Laser and Dermatology Institute
Other
Eligibility
35 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Jun 10, 2026, 2:10 PM EDT
Active, not recruiting Phase 4 Interventional

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

NCT04496362
View directory record Official record
Conditions
ECMO, Heparin, Respiratory Failure
Interventions
subcutaneous heparin anticoagulation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

NCT03512262
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide, Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Greenbrae, California • Simi Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT07090161
View directory record Official record
Conditions
Hypertension, Uncontrolled Hypertension
Interventions
iloperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042
View directory record Official record
Conditions
Obesity and Overweight
Interventions
GZR18, Tirzepatide
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Bessemer, Alabama • Centreville, Alabama • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BT062
Drug
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT05206370
View directory record Official record
Conditions
Smoking Cessation
Interventions
Cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
DeLand, Florida • Fort Myers, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 10, 2026, 2:10 PM EDT
Enrolling by invitation Not applicable Interventional

Adherus™ Dural Sealant in Spinal Procedures

NCT04498026
View directory record Official record
Conditions
Spinal Duraplasty
Interventions
Adherus Dural Sealant System, DuraSeal Exact Dural Sealant System
Device
Lead sponsor
Stryker Craniomaxillofacial
Industry
Eligibility
18 Years to 75 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Duarte, California • Sacramento, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia

NCT01746940
View directory record Official record
Conditions
Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes, of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jun 10, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

NCT00337389
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin, CoFactor (ANX-510)
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
46
States / cities
Florence, Alabama • Anaheim, California • Apple Valley, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2007 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

NCT06542874
View directory record Official record
Conditions
Type 2 Diabetes (T2D)
Interventions
NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Santa Ana, California • Waterbury, Connecticut • Fleming Island, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Topical ASC-J9 Cream for Acne

NCT01289574
View directory record Official record
Conditions
Acne
Interventions
ASC-J9
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

NCT00320710
View directory record Official record
Conditions
Breast Cancer
Interventions
Zoledronic acid, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
92
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Springdale, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 10, 2026, 2:10 PM EDT
Completed Phase 2 Interventional

BMS-741672 for Diabetic Neuropathic Pain

NCT00683423
View directory record Official record
Conditions
Neuropathic Pain
Interventions
BMS-741672, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Tustin, California • Palm Beach Gardens, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jun 10, 2026, 2:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT06065462
View directory record Official record
Conditions
Ovarian Clear Cell Carcinoma
Interventions
Dostarlimab, LB-100
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 2:10 PM EDT